ORIC Pharmaceuticals

General Information


At ORIC, our fully integrated discovery and development team is advancing a diverse pipeline of innovative therapies designed to counter resistance mechanisms in cancer by leveraging our expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. Our lead product candidate, ORIC-101, builds upon a legacy of successful drug development by our founders in the field of nuclear hormone receptors and their efforts to elucidate the cause of resistance to the groundbreaking prostate cancer therapies that they had developed. ORIC-101 is a potent and selective small molecule antagonist of the glucocorticoid receptor (GR), which has been linked to resistance to multiple classes of cancer therapeutics across a variety of solid tumors.

Employees: 57
Founded: 2014
Contact Information
Address 240 E. Grand Avenue, 2nd Floor, South San Francisco, CA 94080, US
Phone Number (650) 388-5600
Web Address http://www.oricpharma.com
View Prospectus: ORIC Pharmaceuticals
Financial Information
Market Cap $460.7mil
Revenues $0 mil (last 12 months)
Net Income $-26.9 mil (last 12 months)
IPO Profile
Symbol ORIC
Exchange NASDAQ
Shares (millions): 7.5
Price range $16.00 - $16.00
Est. $ Volume $120.0 mil
Manager / Joint Managers J.P. Morgan/ Citigroup/ Jefferies/ Guggenheim Securities
CO-Managers -
Expected To Trade: 4/24/2020
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change